February 4, 2020
RegMed Investors’ (RMi) closing bell: the sector soars
February 3, 2020
RegMed Investors’ (RMi) closing bell: the return of the oversold from the coronavirus influence
January 31, 2020
RegMed Investors’ (RMi) closing bell: cavernous cell and gene therapy sector trends
January 30, 2020
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector oozes to another pool of blood
January 29, 2020
RegMed Investors’ (RMi) closing bell: careful as the sector trends
January 28, 2020
RegMed Investors’ (RMi) closing bell: we are not through with scaling the wall of worry
January 27, 2020
RegMed Investors’ (RMi) closing bell: overbought/oversold conditions are both under pressure
January 25, 2020
RegMed Investors' (RMi) closing bell: which risks are playing-out that haven't already been there?
January 23, 2020
RegMed Investors’ (RMi) closing bell: a negative close, after a positive following a negative close and a holiday
January 22, 2020
RegMed Investors’ (RMi) closing bell: the sector grinds and creeps higher
January 21, 2020
RegMed Investors’ (RMi) closing bell: the cell and gene therapy dived
January 17, 2020
RegMed Investors’ (RMi) closing bell: the sector slips and slides
January 16, 2020
RegMed Investors’ (RMi) closing bell: stability hangs in the balance, 7 positive out of 12 closes have kept the cell and gene therapy sector flinching
January 15, 2020
RegMed Investors’ (RMi) closing bell: am I going deaf?
January 14, 2020
RegMed Investors’ (RMi) closing bell: Dow’s barely up as S&P and NASDAQ dive
January 13, 2020
RegMed Investors’ (RMi) closing bell: day one (1) of JPMorgan and a share pricing downer
January 11, 2020
RegMed Investors’ (RMi) closing bell: as I wrote, the downside slide is starting
January 9, 2020
RegMed Investors’ (RMi) closing bell: many share pricing and valuations are tipping the scales
January 8, 2020
RegMed Investors’ (RMi) closing bell: the sector’s rise defused by lightening of political rhetoric
January 7, 2020
RegMed Investors’ (RMi) closing bell: cell and gene therapy pricing was considered a safe bet on Tuesday
January 6, 2020
RegMed Investors’ (RMi) closing bell: fundamentals evolved in the hours of a session
January 3, 2020
RegMed Investors’ (RMi) closing bell: volatility sets the tone for first two trading sessions post a holiday
January 2, 2020
RegMed Investors’ (RMi) closing bell: starting the year with another downside rotation from Tuesday’s close
December 31, 2019
RegMed Investors’ (RMi) closing bell: It’s over, 2019 ends with sadness and some glee
December 30, 2019
RegMed Investors’ (RMi) closing bell: a ringside seat to share price destruction
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.